Kit ligand improves in vitro erythropoiesis in myelodysplastic syndrome
- PMID: 1381239
Kit ligand improves in vitro erythropoiesis in myelodysplastic syndrome
Abstract
Erythropoiesis in response to erythropoietin (Epo) in myelodysplastic syndrome (MDS) in vitro and in vivo is severely impaired. We investigated the stimulative effect of c-kit ligand (KL) on the erythroid colony-forming abilities of bone marrow cells from 17 patients with MDS. The effects of normal donor-derived marrow were examined in comparison. Suppression of erythroid colony formation in MDS in response to Epo could not be restored by the addition of interleukin-3 (IL-3) to culture. In cultures dishes supplemented with KL, erythroid colony formation was dramatically enhanced, regarding both colony number and size. Colony-forming abilities by MDS progenitors were improved following costimulation with KL, particularly in refractory anemia (RA) and refractory anemia with ring sideroblasts (RARS); however, little enhancement was apparent following KL stimulation of marrow from patients with refractory anemia with excess of blasts (RAEB), refractory anemia with excess of blasts in transformation (RAEB-t), and chronic myelomonocytic leukemia (CMML). These results suggest that KL responsiveness of patients with low-risk MDS may still be intact, and that with progression to high-risk MDS, erythroid progenitors lose proliferative reactivity to both KL and Epo stimulation. KL may have a therapeutic role in restoring erythropoiesis in a subset of patients with MDS.
Similar articles
-
Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand.Leukemia. 1996 Mar;10(3):466-72. Leukemia. 1996. PMID: 8642863
-
Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes.Leukemia. 1994 May;8(5):833-8. Leukemia. 1994. PMID: 7514249
-
In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.Clin Cancer Res. 1996 Jun;2(6):1031-8. Clin Cancer Res. 1996. PMID: 9816264
-
[Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].Pathologe. 2000 Jan;21(1):1-15. doi: 10.1007/s002920050001. Pathologe. 2000. PMID: 10663664 Review. German.
-
Myelodysplastic syndromes in the elderly: the role of growth factors in management.Leuk Res. 1996 Mar;20(3):203-19. doi: 10.1016/0145-2126(95)00131-x. Leuk Res. 1996. PMID: 8637215 Review.
Cited by
-
Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.Med Oncol. 2006;23(1):37-49. doi: 10.1385/MO:23:1:137. Med Oncol. 2006. PMID: 16645228 Review.
-
Biology and treatment of myelodysplastic syndromes--developments in the past decade.Ann Hematol. 1993 Mar;66(3):107-15. doi: 10.1007/BF01697618. Ann Hematol. 1993. PMID: 8471655 Review. No abstract available.
-
The effect of stem-cell factor, interleukin-3 and erythropoietin on in vitro erythropoiesis in myelodysplastic syndromes.J Cancer Res Clin Oncol. 1995;121(6):338-42. doi: 10.1007/BF01225685. J Cancer Res Clin Oncol. 1995. PMID: 7797598 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous